# KOMET-007 (NCT05735184)

> A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

No report yet. It can be ordered.

- Drugs tested: ziftomenib plus venetoclax plus azacitidine; ziftomenib plus 7+3; ziftomenib plus venetoclax
- Indication: NPM1-mutated or KMT2Ar acute myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05735184
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Kura Oncology, Inc.
- Conditions: Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML; AML With Mutated NPM1; Acute Myeloid Leukemia Recurrent; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation; KMT2Ar; Myeloid Sarcoma; Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions: Ziftomenib; Venetoclax; Azacitidine; Daunorubicin; Cytarabine; Quizartinib
- Enrollment: 420
- Primary outcome: Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)
- Primary outcome: Descriptive statistics of adverse events
- Primary outcome: Complete remission (CR) rate

## Indexed commentary on KOMET-007 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 13
- Podcasts: 12
- X threads: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=komet-007-nct05735184

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05735184", "email": "<work email>"}; the inbox owner confirms by the emailed link.